IQP-0528 is under clinical development by Statera Biopharma and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IQP-0528’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IQP-0528 is under development for the prevention of sexual transmission of HIV. It is a small molecule administered through rectal and vaginal routes. It is a pyrimidinedione derivative act by targeting nonnucleoside reverse transcriptase (NNRTI).
Statera Biopharma overview
Statera Biopharma is a bio-pharmaceutical company. The company develops and commercializes drugs to treat cancer, orphan indications and protect healthy tissues from radiation and chemotherapy. It product includes entolimod, a recombinant protein that acts as an agonist of toll-like receptor that finds application in radiation mitigation, oncology immunotherapy, and vaccines. Statera Biopharma provides entolimod-oncology, CBLB612, SA-702 – vaccine adjuvant, mobilan, and CBL0137. The company clinical-stage drug candidates are used for the treatment of cancer and protection from lethal radiation. It’s products includes to develop using protectan technology and curaxin technology. The company operates in the US and Russia. Statera Biopharma is headquartered in Buffalo, New York, the US.
For a complete picture of IQP-0528’s drug-specific PTSR and LoA scores, buy the report here.